Eterna Therapeutics (ERNA) Stock Price, News & Analysis

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.31 to $0.34
• 50-Day Range: $0.25 to $0.64
• 52-Week Range: $0.22 to $2.63
• Volume: 584,709 shs
• Average Volume: 633,200 shs
• Market Capitalization: $1.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ERNA Stock Analysis - Frequently Asked Questions

How have ERNA shares performed this year?

Eterna Therapeutics' stock was trading at $0.2940 at the beginning of 2025. Since then, ERNA shares have increased by 7.1% and is now trading at $0.3149.
View the best growth stocks for 2025 here.

How were Eterna Therapeutics' earnings last quarter?

Eterna Therapeutics Inc. (NASDAQ:ERNA) released its earnings results on Tuesday, November, 12th. The company reported ($4.92) earnings per share for the quarter. The company had revenue of $0.49 million for the quarter.

Who are Eterna Therapeutics' major shareholders?

Top institutional investors of Eterna Therapeutics include Geode Capital Management LLC (4.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends.

How do I buy shares of Eterna Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eterna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ERNA
• CUSIP: N/A
• CIK: 748592
• Web: www.brooklynitx.com
• Phone: (212) 582-1199
• Fax: 760-438-3505
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,670,000.00
• Net Margins: -7,513.88%
• Pretax Margin: -7,511.37%
• Return on Equity: N/A
• Return on Assets: -117.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $598,000.00
• Price / Sales: 2.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 5,411,000
• Free Float: 5,168,000
• Market Cap: $1.70 million
• Optionable: No Data
• Beta: 4.29